<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01023217</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-2009-0536</org_study_id>
    <nct_id>NCT01023217</nct_id>
  </id_info>
  <brief_title>Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir</brief_title>
  <acronym>CAESAR</acronym>
  <official_title>Continuation of Lamivudine Plus Adefovir Versus Switching to Entecavir Plus Adefovir in Adults With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Lamivudine Plus Adefovir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The presence of persistent inadequate or suboptimal virologic response is a strong risk
      factor for viral resistance and breakthrough and also for disease progression of chronic
      hepatitis B, and thus, a change in therapy is required. The combination of entecavir (ETV)
      and adefovir (ADV) is a promising treatment for patients with lamivudine (LAM)-resistance who
      show suboptimal response to the combination of LAM and ADV.

      In this randomized, open labeled trial,the investigators will compare the efficacy of
      continuation of ADV plus LAM versus switch to ADV plus ETV in adults with LAM-resistant
      chronic hepatitis B who shows suboptimal response to the combination treatment of ADV and
      LAM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this randomized, open label, two-arm, single center phase IV trial, the investigators will
      assess and compare the efficacy and safety of continuation of ADV plus LAM versus switching
      to ADV plus ETV up to 52-weeks in Korean adults with chronic hepatitis B who have resistant
      mutants to LAM and show suboptimal response to combination of ADV plus LAM.

      All study subjects who complete the initial treatments of 52-weeks will be thereafter treated
      with the combination of ADV plus ETV for 52 more weeks.

      Study period: Nov 2009 - October 2012 Patient enrollment period: November 2009 - December
      2010

      Study protocol

        1. Group A (ADV+LAM group): Adefovir (10 mg/day) + Lamivudine (100 mg/day) for 52 weeks,
           and thereafter, Adefovir (10 mg/day) + Entecavir (1 mg/day) for 52 more weeks

        2. Group B (ADV+ETV group): Adefovir (10 mg/day) + Entecavir (1 mg/day) for 104 weeks
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Virologic Response (CVR, Serum HBV DNA Undetectable by PCR or Less Than 60 IU/mL)</measure>
    <time_frame>at week 52 from randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in Serum HBV DNA Levels</measure>
    <time_frame>at week 52 and at week 104 from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotypic Resistance to ADV or ETV</measure>
    <time_frame>at week 52 and at week 104 from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization of ALT Level</measure>
    <time_frame>at week 52 and at week 104 from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Virologic Response (CVR, Serum HBV DNA Undetectable by PCR or Less Than 60 IU/mL)</measure>
    <time_frame>at week 104 from randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Adefovir plus Entecavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adefovir + Entecavir for 104 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adefovir plus Lamivudine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adefovir + Lamivudine for 52 weeks, and thereafter, Adefovir + Entecavir for 52 more weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir</intervention_name>
    <description>Adefovir dipivoxil (Hepsera) 10 mg/day orally for 104 weeks</description>
    <arm_group_label>Adefovir plus Entecavir</arm_group_label>
    <arm_group_label>Adefovir plus Lamivudine</arm_group_label>
    <other_name>Adefovir dipivoxil (Hepsera)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Entecavir 1 mg/day orally</description>
    <arm_group_label>Adefovir plus Entecavir</arm_group_label>
    <arm_group_label>Adefovir plus Lamivudine</arm_group_label>
    <other_name>Entecavir (Baraclude)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>Lamivudine (Zeffix) 100 mg/day orally</description>
    <arm_group_label>Adefovir plus Lamivudine</arm_group_label>
    <other_name>Lamivudine (Zeffix)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, 16 to 75 years of age

          2. Compensated liver disease(Child-Pugh class A)

          3. HBsAg positive at least 6 months or more

          4. HBeAg positive or negative

          5. Confirmation of Lamivudine-resistance HBV mutation anytime before the study

          6. Patients with suboptimal response (HBV DNA &gt; 2000 IU/mL despite combination of
             Adefovir [10 mg/day] plus Lamivudine [100 mg/day] for 6 months or more). Serum HBV DNA
             should be determined by the PCR assay at the local laboratory at screening for this
             study

          7. Patient is ambulatory.

          8. Patient is willing and able to comply with the study drug regimen and all other study
             requirements.

          9. The patient is willing and able to provide written informed consent to participate in
             the study.

        Exclusion Criteria:

          1. Patient has a history of hepatocellular carcinoma (HCC) or findings suggestive of
             possible HCC, such as suspicious foci on imaging studies or elevated serum alpha
             fetoprotein (AFP) levels. In patients with such findings, HCC should be ruled-out
             prior to randomizing the patient for the present study.

          2. Patient previously received oral antiviral agent other than Lamivudine or Adefovir

          3. Patient has received interferon or other immunomodulatory treatment for HBV infection
             within 12 months before screening for this study.

          4. Patient has concomitant other chronic viral infection (HCV or HIV)

          5. Patient has evidence of renal insufficiency defined as serum creatinine &gt; 1.5 mg/dL

          6. Patient has medical condition that requires use of systemic prednisolone or other
             immunosuppressive agent (including chemotherapeutic agent)

          7. Patient is currently abusing alcohol or illicit drugs, or has a history of alcohol
             abuse or illicit substance abuse within the preceding two years.

          8. Patient is pregnant or breastfeeding or willing to be pregnant

          9. Patient has one or more additional known primary or secondary causes of liver disease,
             other than hepatitis B (e.g., alcoholism, autoimmune hepatitis, malignancy with
             hepatic involvement, hemochromatosis, alpha-1 antitrypsin deficiency, Wilson's
             Disease, other congenital or metabolic conditions affecting the liver, congestive
             heart failure or other severe cardiopulmonary disease, etc.).

         10. A history of treated malignancy (other than hepatocellular carcinoma) is allowable if
             the patient's malignancy has been in complete remission, off chemotherapy and without
             additional surgical intervention, during the preceding three years.

         11. Clinical signs of decompensated liver disease as indicated by any one of the
             following:

               -  serum bilirubin &gt; 3 mg/dL

               -  prothrombin time &gt; 6 seconds prolonged or INR &gt;1.6

               -  serum albumin &lt; 2.8 g/dL

               -  History of ascites, variceal hemorrhage, or hepatic encephalopathy

               -  Child-Pugh score â‰¥7
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-suk Lim, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>the Meteropolis of Seoul</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2009</study_first_submitted>
  <study_first_submitted_qc>December 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2009</study_first_posted>
  <results_first_submitted>November 23, 2013</results_first_submitted>
  <results_first_submitted_qc>November 23, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 13, 2014</results_first_posted>
  <last_update_submitted>January 15, 2014</last_update_submitted>
  <last_update_submitted_qc>January 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Young-Suk Lim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Chronic hepatitis B</keyword>
  <keyword>lamivudine</keyword>
  <keyword>adefovir</keyword>
  <keyword>entecavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Adefovir Plus Lamivudine</title>
          <description>Adefovir (10 mg/day) + Lamivudine (100 mg/day) for 52 weeks, and thereafter, Adefovir (10 mg/day) + Entecavir (1 mg/day) for 52 more weeks
Adefovir plus Lamivudine: Adefovir (10 mg/day) + Lamivudine (100 mg/day) for 52 weeks, and thereafter, Adefovir (10 mg/day) + Entecavir (1 mg/day) for 52 more weeks</description>
        </group>
        <group group_id="P2">
          <title>Adefovir Plus Entecavir</title>
          <description>Adefovir (10 mg/day) + Entecavir (1 mg/day) for 104 weeks
Adefovir plus Entecavir: Adefovir (10 mg/day) + Entecavir (1 mg/day) for 104 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Lamivudine-resistant CHB patients who had failed to respond to lamivudine plus adefovir combination therapy</population>
      <group_list>
        <group group_id="B1">
          <title>Adefovir Plus Entecavir</title>
          <description>Adefovir (10 mg/day) + Entecavir (1 mg/day) for 104 weeks
Adefovir plus Entecavir: Adefovir (10 mg/day) + Entecavir (1 mg/day) for 104 weeks</description>
        </group>
        <group group_id="B2">
          <title>Adefovir Plus Lamivudine</title>
          <description>Adefovir (10 mg/day) + Lamivudine (100 mg/day) for 52 weeks, and thereafter, Adefovir (10 mg/day) + Entecavir (1 mg/day) for 52 more weeks
Adefovir plus Lamivudine: Adefovir (10 mg/day) + Lamivudine (100 mg/day) for 52 weeks, and thereafter, Adefovir (10 mg/day) + Entecavir (1 mg/day) for 52 more weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="11"/>
                    <measurement group_id="B2" value="49" spread="11"/>
                    <measurement group_id="B3" value="47" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Multiple-Drug-Refractory Chronic Hepatitis B Virus Patients</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Virologic Response (CVR, Serum HBV DNA Undetectable by PCR or Less Than 60 IU/mL)</title>
        <time_frame>at week 52 from randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adefovir Plus Entecavir</title>
            <description>Adefovir (10 mg/day) + Entecavir (1 mg/day) for 104 weeks
Adefovir plus Entecavir: Adefovir (10 mg/day) + Entecavir (1 mg/day) for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>Adefovir Plus Lamivudine</title>
            <description>Adefovir (10 mg/day) + Lamivudine (100 mg/day) for 52 weeks, and thereafter, Adefovir (10 mg/day) + Entecavir (1 mg/day) for 52 more weeks
Adefovir plus Lamivudine: Adefovir (10 mg/day) + Lamivudine (100 mg/day) for 52 weeks, and thereafter, Adefovir (10 mg/day) + Entecavir (1 mg/day) for 52 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Virologic Response (CVR, Serum HBV DNA Undetectable by PCR or Less Than 60 IU/mL)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction in Serum HBV DNA Levels</title>
        <time_frame>at week 52 and at week 104 from randomization</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genotypic Resistance to ADV or ETV</title>
        <time_frame>at week 52 and at week 104 from randomization</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Normalization of ALT Level</title>
        <time_frame>at week 52 and at week 104 from randomization</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Virologic Response (CVR, Serum HBV DNA Undetectable by PCR or Less Than 60 IU/mL)</title>
        <time_frame>at week 104 from randomization</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Adefovir Plus Entecavir</title>
          <description>Adefovir (10 mg/day) + Entecavir (1 mg/day) for 104 weeks
Adefovir plus Entecavir: Adefovir (10 mg/day) + Entecavir (1 mg/day) for 104 weeks</description>
        </group>
        <group group_id="E2">
          <title>Adefovir Plus Lamivudine</title>
          <description>Adefovir (10 mg/day) + Lamivudine (100 mg/day) for 52 weeks, and thereafter, Adefovir (10 mg/day) + Entecavir (1 mg/day) for 52 more weeks
Adefovir plus Lamivudine: Adefovir (10 mg/day) + Lamivudine (100 mg/day) for 52 weeks, and thereafter, Adefovir (10 mg/day) + Entecavir (1 mg/day) for 52 more weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc herniation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>URI</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Young-Suk Lim</name_or_title>
      <organization>Asan Medical Center</organization>
      <phone>+82-2-3010-5933</phone>
      <email>limys@amc.seoul.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

